Perfect overview: Seeing the whole picture is essential when treating patients with structural heart disease. Opt for clear image quality that can assist accurate diagnostic assessments for precise device placements in every patient. Have real-time multimodality information in one view. And benefit from partially automated or semi-automated therapy guidance e.g. syngo Aortic Valve Guidance. Empowered by our integrated cardiovascular solutions.
Watch different cases and articles for Structural Heart Disease
What do you think: How many aortic valve replacement performed minimally invasive in Europe?
What do you think: How many people age 65+ can have undiagnosed valvular heart disease?
Fusion imaging with syngo TrueFusion significantly reduced procedure time by 33% and the amount of contrast medium by 30% in patients undergoing LAAC.3
Fusion of CT-defined landmarks to live fluoroscopy in LAAC supports safe and efficient navigation in transseptal puncture and LAA device occluder positioning
Heart Center – Rigshospitalet Copenhagen, Denmark
Heart Center – Rigshospitalet Copenhagen, Denmark
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.
1 European markets for heart valve devices 2014, Millennium Research Group
2 d'Arcy JL, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37:3515–3522. doi:10.1093/eurheartj/ehw229.
3 Contrast volume control group 69.3 ml compared to amount in Fusion group 48.7 ml: syngo TrueFusion in LAA Whitepaper 2021; page 6